Comparative Pharmacology
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus NORPACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus NORPACE.
DISOPYRAMIDE PHOSPHATE vs NORPACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 mL/min), requiring dose adjustment.
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Category D/X
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)